PCT 2017

Clinical trends 2020: Virtual trials, patient recruitment and mobile tech

By Flora Southey contact

- Last updated on GMT

GettyImages/Goldfinch4ever
GettyImages/Goldfinch4ever

Related tags: Clinical trial, Patient

In three years’ time, patients will participate in clinical trials from home and sponsors will proactively recruit subjects, industry experts predict.

In a panel discussion focused on mobile health and technology in Amsterdam yesterday, representatives said the adoption of virtual trials – whereby patients can undertake trials remotely with the help of mobile devices – is on the rise.  

“The world is changing so fast, in three years we will be running virtual trials for sure,” ​Radboud University Medical Centre’s Marjan Faber told delegates at the Partnerships in Clinical Trials conference.

Vice president of mobile health technology at Medidata Solutions – a clinical research technology provider – Anthony Costello similarly said he hopes virtual trials will be commonplace by 2020.

“I would be thrilled to be running virtual trials in three years’ time,” ​he told delegates.

However, AstraZeneca’s Matthew Bonam said he was less optimistic virtual trials would be fully adopted across the industry by that time.

“I think a reasonable target of 70 or 80% of data being collected by the patient in their own home, rather than in centres, is probably achievable and good for everybody,” ​he said.

Patient recruitment

According to Costello, patient identification and recruitment is also a challenge he hopes will be addressed with the help of trial technologies by 2020.

There is a discrepancy between patients who want to adopt virtual trial technology, and doctors who say there is a lack of demand, he told delegates.

“I would hope that over the next three years, we see the distance between these two extremes get smaller,” ​he added.

Costello said he was convinced there is enough patient demand to implement the technology.

“Patients want to give their data and consent, they want to wear devices, they want to make their phone accessible, and they want to participate in a fluid way in this research,” ​we were told.

“I believe the industry is moving in that direction…we could move faster.”

Bonam similarly said patient identification is “the next frontier” ​in the industry, telling delegates further attention is required to identify patients, rather than patients searching for trials themselves.

Clinical research organisation (CRO) Icon’s representative Willie Muehlhausen agreed: “We need to spend more time on patient recruitment and patient education.”

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars